Recommendation of the President – Voxzogo (vosoritide)
On 19 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 128/2024 on the appraisal Voxzogo (vosoritide) as part of the drug program “Treatment of patients with achondroplasia (ICD-10: Q77.4)”